Publication details
Studie PIANIST - trojkombinace v léčbě hypertenze
| Title in English | The PIANIST Study – Triple Combination in the Treatment of Hypertension |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; triple therapy; fixed combination |
| Description | The objective of the PIANIST study was to evaluate a triple-drug antihyper-tensive strategy for blood pressure control in patients with difficult-to-treat hypertension. The Perindopril-Indapamide plus AmlodipiNe in high rISk hy-perTensive patients (PIANIST) trial was an observational, 4-month, open-label study. A total of 4,731 patients at high or very high cardiovascular risk with hypertension that was not properly controlled despite antihypertensive thera-py, and for whom study treatment (fixed-dose perindopril 10 mg/indapamide 2.5 mg, amlodipine 5 or 10 mg) was consistent with their existing therapeutic plan, were included. Results: Mean baseline office blood pressure (OBP) was 160.5 +/- 13.3/93.8 +/- 8.7 mmHg. After 4 months of therapy, OBP decreased by 28.3 +/- 13.5/13.8 +/- 9.4 to 132.2 +/- 8.6/80.0 +/- 6.6 mmHg (p\0.0001). Blood pressu-re targets were reached by 72.0 %of patients and by 81 and 91 % of patients previously treated with an angiotensinconverting enzyme inhibi-tor/hydrochlorothiazide or an angiotensin receptor blocker/hydrochlorothiazide, respectively. Ankle edema was infrequent (0.2 % of patients). Conclusion Triple combination perindopril/indapamide/amlodipine was effectively and safely administered to a large population of high- and very high-risk hypertensive patients who had not reached target OBP values with previous treatment. |